Beam Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Beam Therapeutics Inc. on December 6, 2024, covering events occurring on December 5, 2024. The filing discloses the appointment of a new Chief Financial Officer and related compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change is the appointment of Sravan K. Emany as Chief Financial Officer, effective December 19, 2024. Mr. Emany previously served as CFO and COO of Ironwood Pharmaceuticals, Inc.
Compensation and Management Commentary
The Board approved the following compensation package for Mr. Emany:
- Base Salary: $575,000 annually.
- Sign-on Bonus: One-time payment of $325,000.
- Annual Incentive Bonus: Targeted at 50% of base salary.
- Equity Awards:
- 160,000 incentive stock options with a 10-year term, vesting over four years (25% on first anniversary, remainder monthly).
- 80,000 restricted stock units (RSUs) vesting in four equal annual installments.
- Severance Provisions:
- Termination without cause: 12 months of base salary and COBRA premiums.
- Termination without cause or for good reason near a change in control: 12 months of base salary, target bonus, immediate equity vesting, and COBRA premiums.
Investor Verification Checklist
- Verify the effective start date of the new CFO (December 19, 2024).
- Confirm the exercise price of the stock options, which is tied to the closing price on December 31, 2024.
- Review the vesting schedules for the 160,000 options and 80,000 RSUs to understand future dilution and retention timelines.
- Assess the impact of the $325,000 sign-on bonus and potential annual bonus on near-term cash burn.